2 - |
2
14 00 03 -
,
-
2008 10
208 071 05 123995, , , 2/1
125445, , ,
- , /Ziramet , 2001/, , 2006 , 246 20-79 ( 4,1 ) /Diabetes Atlas, 3rd ed, 2006/ 85-90% 2 , , , , , , 2 (UKPDS) , - , UKPDS 33, 38, 39 /UKPDS, 1998/ / , 2004/, , , , - /Temelkova-Kurktschiev , 2000/, /, , 2003/ , /Grant M , 2000, M , 2004/
, , , , - Continuóse Glucose Monitoring System - /Bode BW ,, 2005/
_
, : ,
: 2
1 2 ,
2 -, - 2 1 0,05
, , , (. ).
6. , __ _
1 (%) 2 (%) 3 (%■)
1 0,05 >0,05 >0,05
0,05 >0,05 >0,05
0,05 >0,05 >0,05
,/ 0,05 >0,05 >0,05
), , / 1-3 7. 7. (̱)
1 2 3 ■
HbAïC, % * 7,90,4 7,8+0,3 7,90,4
, / * 6,4+0,4 6,4+0,4 6,30,3
. ki /2 * 33,81,2 32,4+1,2 30,3+1,3
, . . * 145,33,6 153,94,4 147,1+3,7
, . . * 84,42,1 88,6+2,7 84,3+1,9
(*)->0,05
1-3 , 2 .
1, 2, 4, 8 12- .
1 1 /. 1-2 0,5-1 . 1 .
2 10 /.
3 3 / . 1 . 10 / , . , , 80% .
2 3 (. 8). 22 .
8.
2 , / (/)
. , Diastat Bio-Rad (), 72-
- , /Gross , 2000/ |, 12
, HbAtc 102 >88
= /2(/2) >25 /2 >28 /1 , >30 /2
() (), SPSS 9 0 , 10 /) 13,8+3,4 21,1+6,1 20,82,8
- ( 1 ^ ܸ^ , ;1£
. 6,
, , , .
3
1 - 1 , :: 2008 ::
1. .
1.1. .
1.1.1 .
1.1.2 .
1.2 2 .
1.3. .
2. .
2.1. .
2.1.1. 1.
2.1.2. 2.
2.1.3. 3.
2.2. .
2.3. .
2.3.1. , .
2.3.2. .
2.3.2.1. .
2.3.3. .
2.3.4. .
2.4. .
3.
2 .
3.1. .
3.1.1. ] , ( 1).
3.1.2. 1 , ( 2).
3.1.3. ] , ( 3).
3.1.4. ] 13.
3.1.5. 1.
3.1.6. 2.
3.1.7. 3.
3.1.8. 1-3.
3.1.9.
3.2. .
3.3. .
3.3.1. 13.
3.3.2. 1-3.
3.4. 2 .
3.411. .
3.4.2. 1-3 SF-36.
3.4.3. 1-3.
; . , [151], , , 2006 ., 246 20-79 ( 4,1 ) [58]. 2 85-90% . , 5 *, 1 2006 . 2 533 926 , 2 258 835 - ^ 2 . ^ , , ; 23 . , , , 2 2 , 2,4 [27, 29]. , 2 . ; ; 3 [151, 76]. : 60% ; : ; 10% . ,.> ; , , 2-4 ,, 6-10 , 4-7 [24]. , , ; UKPDS (United Kingdom Prospective Diabetes Study - 2 ). . , .
, , 108 33, 38, 39. , ( 2 ) - 2 [134], (]).
[28]. , , [102], > [68], , .
, . . , .
, , , , . Continuóse Glucose Monitoring System .
, , . ^ .
, , , , .
: 2 .
1. 2 , .
2. -, - 2 1 " 2 "
1. - ] , 2008 , ,
1. . ., . . //. 1989. 9. . 4346.
2. . ., 2007. 112 .
3. . . : // Consilium medicum. 2001. - . 3. - 10. - . 464-468.
4. . . . // . 2004. - 2-3 . - . 91-96.
5. . . - : 2 : . ., 2002.
6. . . 2 . . ., 2003.
7. . ., . . 2: // . 2006. - 3 (118). - . 4753.
8. * . . UKPDS // . 1999. - 4. - .23-27.
9. . ., . ., . . : . . ., 2005. 512 .: . (. . ).
10. . ., . ., . . . () , // . 2003.- 3.- . 20-24.
11. . ., . ., . . / . ., 2000. 60 .
12. .., . . : // . 1992. - 6. - . 26-28.
13. . ., . ., . . . . ., 2004. .8
14. . ., . . ( ). ., 1998.-. 200.
15. . ., . . . ., 2003.
16. . . 2 : : . . - . : 14.00.03 / . . . ., 2000. - 319 .
17. . . II : . . . : 14.00.03 / . -, 1997.- 170 .
18. . . 8 // . 2006. . 52.-3.-.10-12.
19. . . // . 1990. - .36. - 5. - . 3334.
20. . . 2 // . 2002. . 10. - 11. - . 492 498.
21. . ., . ., . . . 2 : // . 2003. - . 9. - 2. - . 67-70.
22. A. JL, . ., . . . - 1 I II // .- 1989.- .35.- 4.-. 3-7.
23. . ., JI. ., . . : , // . 2004.- .12. 6.- . 791-796.
24. . ., . . - 2 // Consilium Medicum. 2003. - .5. 9. - . 504-509.
25. . ., . ., . . - // . 2001. - 4. - . 22-31.
26. // . 2004. - . 10. 2. - . 65-97.
27. . . : , , : . . . . . : 14.00.03 // . . . . . . . ., 1997. - 34 .
28. . . // . . 22-23 . ., 2004.
29. . ., . ., . . : // . 1998.- 1.- .3-11.
30. Amin R., Ross ., Acerini . et al. Hypoglycemia, prevalence in prepubertal children with type 1 diabetes on standart insulin regimen: use of continuous glucose monitoring system // Diabetes Care. 2003. - Vol. 26.- P. 662-667.
31. Ballangi-Pordiny G. et al. Effect of glimepiride on electrical activity of isolated rabbit heart muscle, Arzneim-Forsch // Drug. Res. 1992. Vol. 42(1).- P. 111-113.
32. Barnett A. Treating to goal: challenges of current management // Eur J. Endocrinol. 2004. - Vol. 151(suppl 2). - T 3-7.- discussion T 29^30.
33. Bastyr E. J., Jonson M. E., Trautmann M. E. et al. Insulin lispro in treatment of patients with type 2 diabetes mellitus after oral agent failure // Clin. Ther.- 1999.-Vol. 21.-P. 1703-1714.
34. Bode B. Clinical utility of the continuouse glucose monitoring system // Diabetes Thechnol. Ther. 2000. - Vol. 2. - P. 35^11.
35. Bode ., Gross T., Thornton K. et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study //Diabetes Res. Clin. Pract. 1999. - Vol.46. - P. 183-190:
36. Bode ., Schwartz S., Stubbs H. et al. Glycemic Characteristics in Continuously Monitored Patients with type 1 and type 2 diabetes // Diabetes Care. 2005.- Vol. 26.-10:- P. 2361-2366.
37. Bode ., Hirsch I. Using the Continuous Glucose Monitoring System to improve the management of type 1 diabetes // Diabetes Technol. Ther. -2000. Vol. 2 (suppl. 1). - P. 43-48.
38. Bolli G., DiMarchi R., Park G. et al. Insulin analogs and their potential in the managment of diabetes mellitus // Diabetologia. 1999. - Vol. 42. P.l 151-1167.
39. Bolli G., Owens D. Insulin glargin // Lancet. 2000. - Vol. 356. - P. 443^445.
40. Bonora E., Calcaterra F., Lombardi S. et al. Plasma Glucose-Levels, Throughout the Day and HbAlc Interrelationships in Type 2 Diabetes // Diabetes Care. 2001. - Vol. 24. - P. 2023-2029.
41. Bougneres P., Landier M., Lemniel C. et al. Insulin pump therapy in young children with type 1 diabetes // Pediatr. 1984. - Vol. 105. - P. 212-217.
42. Bowling A. Health-related quality of life: a discussion of concept, its use and measurement. In: Bowling A. Measuring Disease: a Review of Disease Specific Quality of Life Scales // Open University Press. 1995 - Vol.1. P. 19.
43. Bowling A. Measuring Health: a review of quality of life measurement scales. 2th ed. Philadelphia, 1997. - 160 p.
44. Bullinger M., Alonso J., Apolone G. et al. Translating Health Status Questionnaires and Evaluating their Quality: the IQOLA Project Approach // J.Clin.Epidemiol. 1998. - Vol. 51.-11.-P. 913-923.
45. Cameron F., Ambler G. Does continuouse glucose monitoring have clinical utility in contemporary management of diabetes? // Pediatr. Child. Health. 2004. - Vol. 40. - P. 79-84.
46. Ceriello A. The postprandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes / Metabolism research and reviews. 2000. Vol. 16.- P.125-132.
47. Chantelau E., Kohner E. Why some cases of retinopathy worsen when diabetic control improves // British Medical Journal. 1998. - Vol. 315. P. 1105-1106.
48. Chase H., Roberts M., C. Wightman C. et al. Use of the GlucoWatch biographer in children with type 1 diabetes // Pediatrics. 2003. - Vol. 111.- P. 790-794.
49. Clinical practice recommendations / American Diabetes Association // Diabetes Care. 1995. - Vol. 18 (suppl. 1). - P. 1-96.
50. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors / UKPDS Group: U. K. Prospective Diabetes Study VI // Diabetes Res. 1990. - 13.-P. 1-11.
51. Conrad S., Mastrototaro J., Gitelman S. The use of continuouse glucose monitoring system in gypoglicemic disoders // J. Pediatr. Endocrinol. Metab. 2004. - Vol. 17. - P. 281-288.
52. Del Prato S. Postprandial hyperglycemia the necessity for better control. Int Journal of Climcal"Practice. 2000. - Suppl. 112 - P. 3-9:
53. Del Prato S. Significance postprandial blood glucose level // International Journal of Metabolism by fax. 2000. - Vol. 3. - 23. - P. 42.
54. Derr R., Garrett E., Gerald A. et al. Is HbAlc affected by Glycemic Instability? // Diabetes Care. 2003. - Vol. 26. - P. 2728-2733.
55. Diabetes Atlas. 3rd edn. / International Diabetes Federation. Brussels, 2006.
56. Diabetes care and research in Europe: the St. Vinsent Declaration / World Health1 Organization; International Diabetes Federation: Europe // Diabet Med.- 1990.-7.- P. 360.
57. Einhorn D., Sadler C. Fink R. New insights on glycemic control in the ambulatory setting: MiniMed's continuous = glucose monitoring system;// Endo Society 82nd Meeting. 2000. - P. 424.
58. Ferranini E., Natali A., Cerri M. et al. Hypertension: a metabolic disorder? // Diabetes Metabol. 1989. 15. - P: 284-291. .
59. Friedwald W., Levy R., Fredrickson D. Estimation of the concentration of low-density lipoprotein; cholesterol in, plasma; without use of preparation ultracentrifuge // Clin. Chem. 1972. - Vol. 18. - P. 499-509.
60. Funatsu H., Yamashita H., Ohashi Y. Effect of rapid glicaemic control on progression-of diabetic retinopathy // Jpn. J. Ophthalmol. 1992. Vol. 36.- 3.- P. 356-367.
61. Gandek B., Ware J. Methods for validating and norming translations of health status questionnaires: the IQOLA Project approach. International Quality of Life Assessment // J. Clin. Epidemiol-. 1998-Vol. 51. - 11. - P. 953-959.
62. Garg S., Schwartz S., Edelman S. Improved glucose excursions using an implantable real-time continuous glucose sensor in adult with type 1-diabetes // Diabetes Care. 2004. - Vol. 27. - P. 734-738.
63. Glucose tolerance and mortality: comparison of WHO and ADA,diagnostic criteria / The DECODE Study Group; European Diabetes Epidemiology Group // Lancet. 1999: - Vol. 354. - P. 617-621.
64. Grant M., Mames R., Fitzgerald C. et al. The efficacy of octreotide in the therapy of severe nonproliferative and' early proliferative diabetic retinopathy: a randomized controlled study // Diabetes Care. 2000: Vol.23. - P. 504-509.
65. Gross T., Bode B., Einhorn D: et al. Performance evaluation of the MiniMed continuouse glucose monitoring system' during- patient home use // Diabetes Thechnol. Ther. 2000. - Vol. 2. - P; 49-56.
66. Gulli G., Ferrannini E., Stern M: et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents // Diabetes. 1992. - Vol. 41. - P. 1575-1586.
67. Haffner S., Lehto S., Ronnemaa T., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and* in nondiabetic subjectswith and without prior myocardial infarction // N. Engl. J. Med: 1998. Vol. 339.-P. 229-234.
69. Haffner S. Prediction of NIDDM for body fat distribution and hyperinsylinemia // Perspectives hyperinsulinenia. E Standi. - MMV., Munchen, 1990. - P. 32^8.
70. Harris M., Eastman R., Cowie C. et al. Racial and ethnic differences in glycemic control in adults with type 2 diabetes // Diabetes Care. 1999. Vol. 22. - P. 403, 408.
71. Hay L., Wilmshurst E., Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring // Diabetes Thechnol. Ther. -2003.- Vol.5. P. 19-26.
72. Heinemann L., Linkeschova R., Rave K et al. Time-action profile of the long-acting insulin analog insulin glrgine (HOE901) in comparison with those of NPH insulin and placebo // Diabetes Care. 2000. - 23. - P. 644-649.
73. Hughes T., Clements R., Fairclough P. et al. Effect of insulin therapy on lipoproteins in non-insulin-dependent diabetes mellitus (NIDDM) // Atherosclerosis. 1987. - Vol. 67. - P. 105-114.
74. Hume A. Applying Quality of Life Data in Practice. Considerations for antihypertensive therapy // J. of family Practice. 1989. - Vol. 28, 4. P. 403-407.
75. Jovanovic L., Garg S. Improvement in glucose excursions using a seven-day continuous glucose sensor: managing the extremes, 0244 / 42nd EASD Annual Meeting. 2006. - 14-17 Sept.
76. Katz S. The Science of Quality of Life // J. Chron. Dis. 1987. - Vol. 40, 6. - P. 459-463.
77. Kaufman F., Austin J., Neinstein A. et al. Nocturnal hypoglycemia detected with Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes // Pediatr. 2002. - Vol. 141. - P. 625-630.
78. Klonoff D. C. The need for separate performance goals for glucose sensors in the hypoglycemic, normoglycemic and hyperglycemic ranges // Diabetes Care. 2004. - Vol. 27. - P. 734-738.
79. Kramer W., Muller G., Geisen K. Characterization of molecular mode of action of the sulfonilurea, glimepiride at p-cells // Horm. Metab. Res. 1996.- Vol. 28. P. 464-468.
80. Landry D., Oliver J. The ATP-sensitive K+charinel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog // Clin. Invest. 1992. Vol. 89(6). - P. 2071-2074.
81. Landstedt-Hallin L., Adamson U., Arner P. et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure// Diabetes Care. 1995.- Vol.18. P. 1183-1186.
82. Liang M., Shadick N. Feasibility and Utility of Adding Disease-Specific Outcome Measures to a Database to Improve Disease Management // Ann. Intern. Med. 1997. - Vol. 127. - P. 739-742.
83. Ludvigsson J., Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled cross-over study // Pediatrics. 2003. - Vol. 111. P. 933 938.
84. Malmberg K. A., Efendic S., Ryden L. E. Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction. A report from the multicentre trial: DIGAMI // Diabetes Care. 1994. - Vol. 17. - P. 1007-1014.
85. McCall A. L. Clinical review of glimepiride // Expert Opin Pharmacother. -2001.- Vol. 2.- P. 699-713.
86. McCarthy D.Quality of life: A critical assessment // Scand. J. Gastroenterol. -1995. Vol. 30. - Suppl.208. - P. 141-146.
87. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management: 2002 update / American Association of Clinical Endocrinologists // Endocr. Pract. 2002. Vol. 8.- P. 40-83.
88. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients // Diabetes Care. 2003. Vol. 26.- P. 881-885.
89. Mor V. Cancer patients' quality of life over the disease course: lessons from the real world // J. Chron. Dis. 1987. - Vol. 40, 6. - P. 535-544.
90. Muller G., Satoh Y., Geisen K. Extrapancreatic effects of sulfonylureas -a comparison between glimepiride and conventional sulfonylureas // Diabetes Res. Clin. Pract. 1995. - Vol. 28 (suppl.). - P. 115-137.
91. Muller G., Geisen K., Satoh Y. Different interaction of glimepiride and glibenclamide with the p-cell sulfonylurea receptor. I. Binding characteristics //Biochem. Biophys. Acta. 1994.- Vol.1191. - P.267-277.
92. Natan D. M., Buse J. B., Davidson M. B. et al. Management of hyperglycemia in' type 2 diabetes a consensus algorithm for the initiation and adjustment of therapy // Diabetes Care. 2006. - Vol. 29(8). - P. 1963-1971.
93. Overview of 6 years therapy of type II diabetes: a progressive disease / UKPDS Group: U. K. Prospective diabetes study 16. 1995. - Vol. 44. -P. 1249-1258.
94. Ozaki Y. et al. Effects of oral hypoglycemic agents on platelet function // Biochem. Pharmacol. 1992. - Vol. 44. - P. 687-691.
95. Quality of life assessment in clinical trials / Ed. M. J. Staquet, R. D. Hays. Oxford, New York, Tokyo, 1998.- 360 p.
96. Quality of life assessment in clinical trials/ Ed. B. Spilker. New York, 1990.-24 p.
97. Rebrin K., Steil G. M., Van Antwerp W. P. et al. Subcutaneous glucose predicts plasma glucose independent of insulin: implications of continuous monitoring / Am. J. Physiol. 1999. - Vol. 277. - P. 561-571.
98. Riddle M., Rosenstock J. Treatment to target study: insulin glargin vs NPH insulin added to , oral therapy of type 2 diabetes. Successful control with less nocturnal hypoglycemia. HQE901/4002 study // Diabetes. 2002. - Vol. 51 (suppl.2). -P. A113.
99. Rosenstock J:, Schwarts S., Clark C. et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargin (HOE 901): and NPH insulin // Diabetes Care.- 2001:- Vol. 24.-P. 631-636.
100. Saladi S., Zucchini S., Santoni R. et al. The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbAlc in pediatric type 1 diabetic patients // Diabetes Care. 2002. - Vol. 25. - P. 1840-1844.
101. Schmidt F., Stuiter W., Schoonen A. Glucose concentration in subcutaneous extracellular space//Diabetes Care. 1993.-Vol; 16; P. 695-700.
102. Schreiber S., Russman A., Schreiber S. Improved metabolic control with a favorable weight profile in patients with type 2 diabetes treated with insulin glargin in clinical practice // Diabetes. 2002. Vol. 51(suppl 2): A 114. Abstract 464-P.
103. Second report on diabetes mellitus. Technical report series 646 / World Health Organization Expert Committee. Geneva; 1980.
104. Shichiri M., Kishikawa H., Ohkubo Y. et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients // Diabetes Care. 2000. - Vol. 23. - P. 21-29.
105. Sjolie A., Moller F. Medical management of diabetic retinopathy // Diabetic Medicine. 2004. - Vol. 21. - P. 666-672.
106. Slama G. Clinical significance of post-prandial blood glucose excursions in type 1 and 2 diabetes mellitus // Int. Journal of Clinical Practice. 2000. Suppl. 112.-P. 9-13.
107. Spitzer W.O. State of Science 1986: Quality of Life and Functional Status as Target Variables for Research // J. Chron. Dis. 1987. - Vol. 40, 6. P.465-471.
108. Standards of medical care in diabetes (Position Statement) / American Diabetes Association // Diabetes Care. 2004. - Vol. 27. - P. 15-35.
109. Sternberg F., Meyerhoff C., Mennel F. et al. Subcutaneouse glucose concentration in humans: real estimation and continuous monitoring // Diabetes Care. 1995. - Vol. 18. - P. 1266-1269.
110. Study design, progress and performance / UKPDS Group: U. K. Prospective Diabetes Study VIII // J. Diabetologia. 1991. - 34. - P. 877-890:
111. Summary of safety and effectiveness data for the MiniMed Continuous Glucose Monitoring System (CGMS). PMA P980022, Food and Drug Administration article online., 1999. Available from http://www.fda.gov/cdrh/pdf/p980022.html.
112. Sweet J., Breuer S., Hazlewood L. et al. The Million Behavioral Health Inventory: Concurrent and Predictive Validity in a Pain Treatment Center // J. Behavioral Medicine. 1985. - Vol. 8, 3. - P. 215-226.
113. Tanenberg R., Bode B., Lane W. et al. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial // Mayo Clin. Proc. 2004. - Vol. 79. - P. 1521-1526.
114. Taskinen M., Kuusi T., Helve E. et al. Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulin-dependent diabetes // Aterosclerosis. 1988. - Vol. 8. - P. 168-177.
115. Tavris D., Shoaibi A. The public health impact of the MiniMed Continuouse glucose monitoring system (CGMS) an assessment of the literature // Diabetes Technol. Ther. - 2004.- Vol.6. - P. 518-522.
116. Temelkova-Kurktschiev T., Koehler C., Henkel E. et al. Postchallenge plazma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbAl'c level // Diabetes Care. -2000. Vol. 23. - P. 1830-1834.
117. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes /s
118. Diabetes Control and Complication Trial Research Group // N. Engl. J. Med. 1993. - Vol. 329. - P. 977-986.
119. The Efficacy and Safety of Glimepiride in the Management of Type 2 Diabetes in- Muslim- Patients During Ramadan / The Glimepiride in Ramadan Study Group (GLIRA) // Diabetes Care. 2005. - Vol. 28. - P.421.422.
120. The teaching letters / Diabetes Education Study Group of the EASD. -Geneva, 1985.
121. Troidl H., Kusche J., Vestweber K. et al. Quality of life an important Endpoint Both in surgical practice and reseach // J. Chron. Dis. 1987. -Vol. 40(6). -P.523-528.
122. Tsunekawa T., Hayashi T., Suzuki Y. et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in eldely type 2 diabetic subjects // Diabetes Care. 2003. Vol. 26. - P. 285-289.
123. Ware J., Snow K., Kosinski M. et al. Sf-36 health survey: Manual and Interpretation guide. Boston, 1993.
124. Ware J., Sherbourne C. The MOS 36-item short-form health survey (SF 36): conceptual framework and item selection // Med. Care. 1992. Vol. 30. - P. 473-485.
125. Ware J., Gandek B. Methods .for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International Quality of Life Assessment/J.Clin. Epidemiol. 1998. - Vol. 51. - 11.- P. 945-952.
126. Weinzimer S., Tamborlane W., Chase H. et al. Continuouse glucose monitoring in type 1 diabetes // Curr. Diab. Rep. 2004. - Vol. 4. - P. 95-100.
127. Welschen L., Bloemendal E., Nijpels G. et al. Self-monitoring-of blood-glucose in patient with type 2 diabetes who are not using insulin: a systematic review // Diabetes Care. 2005. - Vol. 28: - P. 1510-1517.
128. Wenger N., Mattson M., Furberg C. et al. Assessment of Quality of Life in clinical trials of cardiovascular therapies // Am. J. Cardiol. 1984.1. Vol. 54.- P. 908-913.
129. Williams E., Klesges R., Hanson C. et al. A prospective study of the reliability and convergent validiity of three physical activity measures in a field research trial // J. Clin. Epidemiol. 1989. - Vol. 42, 13. - P.1161-1170.
130. Wright A. et al. Sulfonilurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes mellitus in U.K. prospective Diabetes Study (UKPDS 57) // Diabetes Care. 2002. - Vol. 25. - P. 330336.
131. Yki-Jarvinen H. Combination Therapies with Insulin in Type 2 // Diabetes Care. 2001. - Vol. 24(4). - P. 758-767.
132. Yki-Jarvinen H., Kauppila M., Kujansuu E. et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus // N. Engl. J. Med. 1992. - Vol. 327. - P. 1426-1433.
133. Zimmet P., Alberti K., Shaw J. Global and societal implications of the diabetic epidemic //Nature. 2001. - Vol. 414. - P. 782-787.
: | 2 1 1 |